Form 8-K - Current report:
SEC Accession No. 0000950170-25-070371
Filing Date
2025-05-13
Accepted
2025-05-13 16:15:09
Documents
13
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evok-20250513.htm   iXBRL 8-K 46706
2 EX-99.1 evok-ex99_1.htm EX-99.1 288289
3 GRAPHIC img208171256_0.jpg GRAPHIC 27817
  Complete submission text file 0000950170-25-070371.txt   500366

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20250513.xsd EX-101.SCH 23903
15 EXTRACTED XBRL INSTANCE DOCUMENT evok-20250513_htm.xml XML 4534
Mailing Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 25940296
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)